Alexion Overview

  • Year Founded
  • 1992

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 4,759

Employees

  • Latest Deal Type
  • M&A

  • Latest Deal Amount
  • $41.1B

Alexion General Information

Description

Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating conditions. The company is involved in biotechnology research and offers therapies that treat paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD) among others, enabling individuals to overcome the issues they face every day.

Contact Information

Website
www.alexion.com
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • 121 Seaport Boulevard
  • Boston, MA 02210
  • United States
+1 (475)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Parent Company
AstraZeneca
Corporate Office
  • 121 Seaport Boulevard
  • Boston, MA 02210
  • United States
+1 (475)

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alexion Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 21-Jul-2021 $41.1B Completed Profitable
9. Merger/Acquisition 06-Dec-2019 Cancelled Profitable
8. Debt Refinancing 30-Apr-2018 Completed Profitable
7. PIPE 10-Mar-2018 Completed Profitable
6. PIPE 06-Aug-2017 Completed Profitable
5. Debt - Acquisition 23-Jun-2015 Completed Profitable
4. 2PO 23-May-2012 Completed Profitable
3. Debt - Acquisition 31-Jan-2012 Completed Profitable
2. IPO 28-Feb-1996 Completed Profitable
1. Early Stage VC 01-Jan-1994 Completed Profitable
To view Alexion’s complete valuation and funding history, request access »

Alexion Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Dveloper of biopharmaceutical drugs intended to transform the lives of people affected by rare diseases and devastating
Drug Discovery
Boston, MA
4,759 As of 2024

Gaithersburg, MD
 

Leuven, Belgium
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alexion Competitors (41)

One of Alexion’s 41 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
NexImmune Formerly VC-backed Gaithersburg, MD
TiGenix Formerly VC-backed Leuven, Belgium
Hansa Biopharma Corporation Lund, Sweden
Cristal Therapeutics Venture Capital-Backed Maastricht, Netherlands
Genentech Formerly VC-backed South San Francisco, CA
You’re viewing 5 of 41 competitors. Get the full list »

Alexion Patents

  • 1,958

    Total Documents Applications and Grants

  • Total Patents Families

  • 871

    Granted

  • 308

    Pending

  • Expiring in next 12 mo

Alexion Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023352679-A1 Dosage and administration of anti-c5 antibodies for preventing or minimizing cardiac surgery associated acute kidney injury (csa-aki) and/or subsequent major adverse kidney events (make) in patients with chronic kidney disease Pending 28-Sep-2022
AU-2023338677-A1 Supplemental dosage and administration of anti-c5 antibodies for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma) Pending 06-Sep-2022
AU-2023280383-A1 Dosage and administration of fusion polypeptides for treatment of myasthenia gravis Pending 03-Jun-2022
EP-4532533-A2 Dosage and administration of fusion polypeptides for treatment of myasthenia gravis Pending 03-Jun-2022
EP-4522988-A1 High sensitivity biotinylated peptide binding elisa assay Pending 11-May-2022 C07K16/18
To view Alexion’s complete patent history, request access »

Alexion Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alexion Former Investors (17)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alkeon Capital Management Venture Capital Minority
BB Biotech Asset Manager Minority
BMO Financial Group Corporation Minority
Bank of the West Corporation Minority
CHL Medical Partners Venture Capital Minority
You’re viewing 5 of 17 investors. Get the full list »

Alexion Investments & Acquisitions (27)

Alexion’s most recent deal was a Corporate Asset Purchase with Pfizer (Early-Stage Gene Therapy Portfolio) for . The deal was made on 20-Sep-2023.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Pfizer (Early-Stage Gene Therapy Portfolio) 20-Sep-2023 Corporate Asset Purchase Buildings and Property
Verge Genomics 08-Sep-2023 Later Stage VC Drug Discovery
LogicBio Therapeutics 16-Nov-2022 Merger/Acquisition Biotechnology
Caelum Biosciences 06-Oct-2021 Merger/Acquisition Biotechnology
Rhythm Pharmaceuticals (Rare Pediatric Disease Priority Review Voucher in Boston, Massachusetts) 01-Feb-2021 Corporate Asset Purchase Buildings and Property
You’re viewing 5 of 27 investments and acquisitions. Get the full list »

Ready to get started?

Request a free trial

Alexion ESG

Risk Overview

Risk Rating

Updated March, 25, 2022

14.78 | Low Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 15,480

Rank

Percentile

Pharmaceuticals

Industry

of 905

Rank

Percentile

Biotechnology

Subindustry

of 404

Rank

Percentile

To view Alexion’s complete esg history, request access »

Alexion Affiliates

Subsidiaries (2)

Name Industry Location Year Founded
Complement Pharma Amsterdam, Netherlands 2009
Prothelia Milford, MA 2007

Alexion FAQs

  • When was Alexion founded?

    Alexion was founded in 1992.

  • Where is Alexion headquartered?

    Alexion is headquartered in Boston, MA.

  • What is the size of Alexion?

    Alexion has 4,759 total employees.

  • What industry is Alexion in?

    Alexion’s primary industry is Drug Discovery.

  • Is Alexion a private or public company?

    Alexion is a Private company.

  • What is the current valuation of Alexion?

    The current valuation of Alexion is .

  • What is Alexion’s current revenue?

    The current revenue for Alexion is .

  • How much funding has Alexion raised over time?

    Alexion has raised $3.61B.

  • Who are Alexion’s investors?

    Alkeon Capital Management, BB Biotech, BMO Financial Group, Bank of the West, and CHL Medical Partners are 5 of 17 investors who have invested in Alexion.

  • Who are Alexion’s competitors?

    NexImmune, TiGenix, Hansa Biopharma, Cristal Therapeutics, and Genentech are some of the 41 competitors of Alexion.

  • When was Alexion acquired?

    Alexion was acquired on 21-Jul-2021.

  • Who acquired Alexion?

    Alexion was acquired by AstraZeneca.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »